<DOC>
	<DOCNO>NCT00335959</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy together radiation therapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well give oxaliplatin capecitabine together radiation therapy work treat patient stomach cancer remove surgery .</brief_summary>
	<brief_title>S0425 Oxaliplatin , Capecitabine , RT Treating Patients W/Stomach Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine pathologic complete response rate patient primary gastric adenocarcinoma treat neoadjuvant chemoradiotherapy comprise oxaliplatin , capecitabine , radiotherapy . ( This complete study close early due poor accrual . ) - Assess frequency severity toxicity associate regimen . - Explore , preliminarily , association DNA repair gene ( ERCC-1 , XRCC1 , GST-P1 , XPD , XPA , ribonucleotide reductase ) , target enzyme ( thymidylate synthase [ TS ] , dihydropyrimidine dehydrogenase , thymidine phosphorylase [ TP ] ) , angiogenic factor ( vascular endothelial growth factor [ VEGF ] , epidermal growth factor [ EGF ] , PD-ECGF , basic fibroblast growth factor , TSP-1 -2 , transform growth factor [ TGF ] -β , IL-8 ) response neoadjuvant therapy patient adenocarcinoma stomach . ( This complete study close early due poor accrual . ) - Explore , preliminarily , association haplotype candidate gene TS , TP , ERCC-1 , XPD , GST-P1 , cyclooxygenase-2 , EGF receptor , TGF-β , VEGF , IL-8 response toxicity neoadjuvant chemoradiation therapy patient . ( This complete study close early due poor accrual . ) - Explore , preliminarily , feasibility perform comparative genomic hybridization analysis DNA copy number change predict response neoadjuvant chemoradiation therapy . ( This complete study close early due poor accrual . ) OUTLINE : This multicenter , pilot study . - Neoadjuvant chemotherapy : Patients receive oxaliplatin IV 2 hour day 1 22 oral capecitabine twice daily day 1-14 22-35 absence disease progression unacceptable toxicity . - Neoadjuvant chemoradiotherapy : Patients receive oral capecitabine twice daily day 43-77 undergo radiotherapy daily day 43-47 , 50-54 , 57-61 , 64-68 , 71-75 absence disease progression unacceptable toxicity . - Surgery : Patients stable respond disease undergo surgery 4-6 week completion chemoradiotherapy . Tumor tissue obtain surgery endoscopic biopsy . Gene expression analysis comparative genomic hybridization test conduct tissue . Blood drawn prior begin study treatment analyze germline polymorphism . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 75 patient accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary adenocarcinoma stomach , meet follow criterion : Newly diagnose disease amenable curative resection Stage IBIII ( T24 ) Measurable nonmeasurable disease Enlarged lymph node outside radiation field must preoperative biopsy No positive lymph node outside radiation field No distant metastasis No gastroesophageal junction tumor PATIENT CHARACTERISTICS : Zubrod performance status 01 Absolute neutrophil count ≥ 1,500/mm³ WBC ≥ 3,000/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 time upper limit normal Albumin ≥ 3 g/dL Bilirubin normal No evidence ischemic heart disease EKG No coronary artery disease require active medical treatment No symptom angina No history myocardial infarction No deep vein thrombosis within past 12 month No preexist peripheral neuropathy No active pneumonia inflammatory lung infiltrate No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease free ≥ 5 year No clinically significant comorbid medical condition would prevent delivery chemotherapy , radiotherapy , performance surgery Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : At least 4 week since prior concurrent sorivudine brivudine No prior therapy malignancy , include chemotherapy , surgery , immunotherapy , radiotherapy No prior coronary angioplasty stenting No concurrent 2dimensional intensitymodulated radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
</DOC>